UK biologics market is estimated to grow at a CAGR of 7.8% during the forecast period. Rising cancer incidences and significant trend towards cell and gene therapy are some key factors accelerating the market growth. As per the World Health Organization (WHO), in 2020, the new cancer incidences which is expected to be reported will be 457,960. This is driving the adoption of biologics drugs serves as an immune system substance that supports to enhance the body’s ability to fight against cancer. Types of biological drugs comprise vaccines, allergens, blood, tissues, recombinant proteins, blood components, cells, and genes. Biologic products may comprise genes that control the development of vital proteins. These proteins support to control the action of other proteins and cellular processes, cells, or modified human hormones, that develop substances that activate or suppress components of the immune system. 

Visit for Global Biologics Market Report at: https://www.omrglobal.com/industry-reports/biologics-market

UK biologics market is segmented based on product and application. Based on the product, the market is segmented into antibody therapeutics, vaccines, cell therapy, gene therapy, and others. Increasing focus on approvals of gene therapies is driving the growth of the market. COVID-19 pandemic has accelerated the development of antibody therapeutics in the country. In June 2020, AstraZeneca granted support from the US government which is intended to progress the development of antibody-based COVID-19 therapeutics. The company accelerating efforts beyond its potential vaccine to combat the COVID-19. Based on application, the market is segmented into cancer, autoimmune diseases, infectious diseases, and others. 

Some prominent players in the market include AstraZeneca plc, AbbVie Inc., GlaxoSmithKline plc, F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH. The market players are using some key strategies to increase their market share. For instance, in May 2020, Crescendo Biologics Ltd. and Cancer Research UK declared a Clinical Development Partnership to advance one of the Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials that targets cancers of high unmet medical requirements. Under the agreement, Cancer Research UK will fund in the future Phase I clinical trial for CB213, in patients suffering from solid tumours. 

Research Methodology

The market study of the UK biologics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Biologics Market Research and Analysis by Product
2. UK Biologics Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the UK biologics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK biologics market.
• Insights about market determinants which are stimulating the UK biologics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.